Literature DB >> 17283579

Fine specificity of the Ro/SSA autoantibody response in relation to serological and clinical findings in 96 patients with self-reported cutaneous symptoms induced by the sun.

K Popovic1, S Brauner, M Ek, M Wahren-Herlenius, F Nyberg.   

Abstract

Anti-Ro/SSA assays assist the clinician in distinguishing autoimmune diseases such as Sjögrenś syndrome (SS), systemic lupus erythematosus (SLE) and subacute cutaneous lupus erythematosus (SCLE). The objective of the study was to investigate the fine specificity of the autoantibodies in relation to clinical presentation as well as environmental and endogenous factors such as photosensitivity, smoking and immunoglobulin (Ig) levels in patients with Ro/SSA autoantibodies. Serum samples from 96 anti-Ro/SSA positive photosensitive patients were tested for autoantibody levels by enzyme-linked immunosorbent assay (ELISA) using purified recombinant Ro52 kd, Ro60 kd and La proteins as antigens. The highest levels of anti-Ro52 and anti-La were observed in patients with primary SS, and the lowest levels of anti-Ro52 in chronic cutaneous lupus erythematosus (CCLE). SCLE patients with systemic disease (SLE and/or SS) showed higher levels of anti-Ro52 than SCLE limited to the skin. A correlation between high serum levels of IgG and anti-Ro52 (P < 0.01) and between IgA and anti-Ro52 (P < 0.05) and anti-Ro60 (P < 0.05) was found. Polymorphic light eruption (PLE) was common in all diagnostic groups but did not correlate with autoantibody levels. Smoking was more common in lupus patients than in SS patients. Our findings thus propose different mechanisms for different clinical presentations of Ro/SSA positive patients. The testing of anti-Ro52 antibodies might serve as a prognostic tool in photosensitive cutaneous diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17283579     DOI: 10.1177/0961203306073135

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  7 in total

1.  Anti-tubulin-α-1C autoantibody in systemic lupus erythematosus: a novel indicator of disease activity and vasculitis manifestations.

Authors:  Xiaozhen Zhao; Yongjing Cheng; Yuzhou Gan; Rulin Jia; Lei Zhu; Xiaolin Sun
Journal:  Clin Rheumatol       Date:  2018-02-09       Impact factor: 2.980

Review 2.  Autoantibodies and SLE: the threshold for disease.

Authors:  Nancy J Olsen; David R Karp
Journal:  Nat Rev Rheumatol       Date:  2013-12-03       Impact factor: 20.543

3.  Autoantibodies from mice exposed to Libby amphibole asbestos bind SSA/Ro52-enriched apoptotic blebs of murine macrophages.

Authors:  David J Blake; Scott A Wetzel; Jean C Pfau
Journal:  Toxicology       Date:  2008-01-19       Impact factor: 4.221

4.  Extended B cell phenotype in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional study.

Authors:  F Mensah; A Bansal; S Berkovitz; A Sharma; V Reddy; M J Leandro; G Cambridge
Journal:  Clin Exp Immunol       Date:  2016-02-22       Impact factor: 4.330

5.  Polymorphisms of the ITGAM gene confer higher risk of discoid cutaneous than of systemic lupus erythematosus.

Authors:  Tiina M Järvinen; Anna Hellquist; Sari Koskenmies; Elisabet Einarsdottir; Jaana Panelius; Taina Hasan; Heikki Julkunen; Leonid Padyukov; Marika Kvarnström; Marie Wahren-Herlenius; Filippa Nyberg; Mauro D'Amato; Juha Kere; Ulpu Saarialho-Kere
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

Review 6.  Current Insights in Cutaneous Lupus Erythematosus Immunopathogenesis.

Authors:  Colton J Garelli; Maggi Ahmed Refat; Padma P Nanaware; Zaida G Ramirez-Ortiz; Mehdi Rashighi; Jillian M Richmond
Journal:  Front Immunol       Date:  2020-07-02       Impact factor: 7.561

7.  Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases.

Authors:  Ailsa Robbins; Maxime Hentzien; Segolene Toquet; Kevin Didier; Amelie Servettaz; Bach-Nga Pham; Delphine Giusti
Journal:  Front Immunol       Date:  2019-03-12       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.